Form 4: FibroGen CEO Wettig Thane Reports Stock Transactions

FibroGen CEO Thane Wettig reports acquisition and disposal of company stock related to vesting of restricted stock units and PSU milestone grant.

Summary

• On March 6, 2024, FibroGen CEO Thane Wettig reported transactions involving FibroGen stock.
• 4,209 shares were disposed of to cover tax obligations at a price of $1.87 per share.
• 781 shares were acquired related to a PSU Milestone Grant vesting.
• An additional 326 shares were withheld by the issuer to cover tax obligations related to the PSU Milestone grant at a price of $1.87 per share.
• Following these transactions, Wettig directly owns 420,178 shares of common stock and indirectly owns 1,000 shares through a spouse.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing reflects routine transactions related to executive compensation and tax obligations.

Positives

• The vesting of the PSU Milestone Grant suggests the achievement of certain performance targets.

Industry Context

Form 4 filings are standard disclosures required by the SEC for corporate insiders, providing transparency into their trading activities. These filings are closely watched by investors for signals about management's view of the company's prospects.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for all publicly traded companies in the United States.
• The information provided in this Form 4 is consistent with the type of information disclosed by executives at comparable biotechnology companies such as Amgen, Biogen, and Gilead Sciences when they engage in similar transactions.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they primarily reflect internal compensation adjustments.

Key Dates